Pharsight Launches New DMX(TM) Web Server

Pharsight Corporation (OTCBB:PHST), a leading provider of software and strategic services designed to optimize clinical drug development, today announced the release of the Drug Model Explorer™ Web Server(DMX™). DMX is a fully commercialized software tool that allows users to quickly and easily access and utilize key data contained within drug and disease models. Pharsight believes this technology will increase the value of modeling and simulation to the drug development process.

DMX is a web-based tool that allows clinical drug development teams to communicate, present and exchange information quickly and efficiently across the enterprise and compare probable outcomes based on different treatment strategies, patient populations and competing products. As an interactive, enterprise-wide portal, DMX can be used by developers to access drug candidate profiles and modeling data within the organization. By serving as a knowledge portal, and accurately illustrating a wide range of scenarios, DMX can enhance the developer’s understanding of a drug’s likely clinical potentials and limitations, and enable more efficient decision-making. Pharsight believes that DMX will help further streamline the drug development process, which is estimated to be as much as $800 million per drug, by replacing the clients’ current disparate decision making techniques.

“We believe that the DMX Web Server provides mission critical functionality for clinical scientists,” said Shawn M. O’Connor, president and chief executive officer. “DMX is a dynamic and flexible software application that reduces the existing barriers to accessing key information and insights contained within drug models. When we initially introduced our desktop DMX application to the top five pharmaceutical companies, we received an overwhelmingly positive response and decided to engineer an enterprise software product that would support an even greater level of collaboration. By providing the necessary tools, we believe that our unique technology will foster the ongoing adoption by the pharmaceutical industry of an integrated, quantitative, model-based approach to drug development.”

Key features and functionality of DMX include:

· Ability to Rapidly Answer “What-If” Questions:DMX offers a flexible browser-based software application to understand the probability of a drug’s likely clinical profiles for various scenarios by allowing users to quickly compare expected outcomes across a variety of drug models and inputs.

· Flexible Model-Based Results:DMX provides entire project teams and decision-makers the ability to directly interact with modeling results, removing the need for everyone to familiarize themselves with complicated modeling techniques and methodologies in order to grasp the key insights provided by modeling and simulation.

· Central Repository:DMX offers a centralized and interactive visual exchange of model-based data, facilitating real-time management, access, discussion and presentation. This information can be easily updated when new data is available.

· Scalable and Easy to Deploy:DMX is supported by three-tier architecture and components compatible with the pharmaceutical industry standards and existing technology infrastructure.

About Pharsight Corporation

Pharsight Corporation (OTCBB: PHST) develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers’ development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at http://www.pharsight.com